Active surveillance as a practical strategy to differentiate lethal and non-lethal prostate cancer subtypes

Area of Science:

• Oncology
• Urology
• Cancer Research

Background:

• Prostate-specific antigen (PSA) screening has decreased prostate cancer mortality by over 20%.
• Distinguishing lethal from non-lethal prostate cancer is crucial to prevent overtreatment.
• Identifying patients who benefit from immediate intervention versus active surveillance remains challenging at diagnosis.

Purpose of the Study:

• To review the benefits and risks associated with active surveillance for prostate cancer.
• To explore future strategies for enhancing active surveillance programs.

Main Methods:

• Literature review of active surveillance protocols and outcomes in prostate cancer management.
• Discussion of current challenges in patient selection for active surveillance.
• Exploration of emerging technologies and biomarkers.

Main Results:

• Active surveillance offers a viable strategy to minimize overtreatment in select prostate cancer patients.
• Careful patient selection is key to the success of active surveillance programs.
• Imaging and novel biomarkers show promise for improving active surveillance outcomes.

Conclusions:

• Active surveillance is a critical tool for managing prostate cancer, balancing treatment benefits against risks.
• Further research into advanced imaging and biomarkers is essential for refining active surveillance protocols.
• Optimizing active surveillance can lead to improved patient outcomes and reduced healthcare burdens.